Abbott Laboratories (ABT) operating KPIs

ABTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value

$106.20+1.63 (+1.56%)

Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%

Abbott Laboratories total Inventories ($M) ($M)

Postgres DB financial_values + XBRL

Quarterly Annual

Latest, Q2 2026

7,315

Period ended Jun 30, 2026

Change on a year earlier

+5.2%

6,954 in Q2 2025

History

71 quarters

Since Q4 2007

Sources

Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	Total Inventories ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	7,315	+5.2%	Form 10-Q (filed 2026-07-28) ↗
Q1 2026	Mar 31, 2026	6,989	+5.3%	Form 10-Q (filed 2026-04-29) ↗
Q4 2025	Dec 31, 2025	6,488	+4.7%	Form 10-K (filed 2026-02-20) ↗
Q3 2025	Sep 30, 2025	6,708	-1.5%	Form 10-Q (filed 2025-10-29) ↗
Q2 2025	Jun 30, 2025	6,954	+2.1%	Form 10-Q (filed 2025-07-30) ↗
Q1 2025	Mar 31, 2025	6,639	-2.8%	Form 10-Q (filed 2025-04-30) ↗
Q4 2024	Dec 31, 2024	6,194	-5.7%	Form 10-K (filed 2025-02-21) ↗
Q3 2024	Sep 30, 2024	6,813	+2.5%	Form 10-Q (filed 2024-10-31) ↗
Q2 2024	Jun 30, 2024	6,814	-0.8%	Form 10-Q (filed 2024-07-31) ↗
Q1 2024	Mar 31, 2024	6,827	+2.3%	Form 10-Q (filed 2024-05-02) ↗
Q4 2023	Dec 31, 2023	6,570	+6.4%	Form 10-K (filed 2024-02-16) ↗
Q3 2023	Sep 30, 2023	6,650	+16.0%	Form 10-Q (filed 2023-11-01) ↗
Q2 2023	Jun 30, 2023	6,871	+16.5%	Form 10-Q (filed 2023-08-03) ↗
Q1 2023	Mar 31, 2023	6,673	+17.3%	Form 10-Q (filed 2023-05-04) ↗
Q4 2022	Dec 31, 2022	6,173	+19.7%	Form 10-K (filed 2023-02-17) ↗
Q3 2022	Sep 30, 2022	5,734	+9.0%	Form 10-Q (filed 2022-11-01) ↗
Q2 2022	Jun 30, 2022	5,899	+8.5%	Form 10-Q (filed 2022-08-02) ↗
Q1 2022	Mar 31, 2022	5,691	+5.6%	Form 10-Q (filed 2022-05-03) ↗
Q4 2021	Dec 31, 2021	5,157	+2.9%	Form 10-K (filed 2022-02-18) ↗
Q3 2021	Sep 30, 2021	5,261	+2.1%	Form 10-Q (filed 2021-11-03) ↗
Q2 2021	Jun 30, 2021	5,439	+4.6%	Form 10-Q (filed 2021-08-04) ↗
Q1 2021	Mar 31, 2021	5,387	+17.9%	Form 10-Q (filed 2021-05-05) ↗
Q4 2020	Dec 31, 2020	5,012	+16.1%	Form 10-K (filed 2021-02-19) ↗
Q3 2020	Sep 30, 2020	5,152	+17.3%	Form 10-Q (filed 2020-11-04) ↗
Q2 2020	Jun 30, 2020	5,202	+19.5%	Form 10-Q (filed 2020-07-29) ↗
Q1 2020	Mar 31, 2020	4,568	+11.8%	Form 10-Q (filed 2020-04-29) ↗
Q4 2019	Dec 31, 2019	4,316	+13.7%	Form 10-K (filed 2020-02-21) ↗
Q3 2019	Sep 30, 2019	4,392	+16.2%	Form 10-Q (filed 2019-10-31) ↗
Q2 2019	Jun 30, 2019	4,352	+17.2%	Form 10-Q (filed 2019-07-31) ↗
Q1 2019	Mar 31, 2019	4,085	+6.8%	Form 10-Q (filed 2019-05-01) ↗
Q4 2018	Dec 31, 2018	3,796	+5.4%	Form 10-K (filed 2019-02-22) ↗
Q3 2018	Sep 30, 2018	3,781	+8.6%	Form 10-Q (filed 2018-10-31) ↗
Q2 2018	Jun 30, 2018	3,714	+3.1%	Form 10-Q (filed 2018-08-01) ↗
Q1 2018	Mar 31, 2018	3,826	-4.2%	Form 10-Q (filed 2018-05-02) ↗
Q4 2017	Dec 31, 2017	3,601	+47.9%	Form 10-K (filed 2018-02-16) ↗
Q3 2017	Sep 30, 2017	3,483	+33.3%	Form 10-Q (filed 2017-11-02) ↗
Q2 2017	Jun 30, 2017	3,603	+28.1%	Form 10-Q (filed 2017-08-02) ↗
Q1 2017	Mar 31, 2017	3,995	+43.4%	Form 10-Q (filed 2017-05-03) ↗
Q4 2016	Dec 31, 2016	2,434	-6.3%	Form 10-K (filed 2017-02-17) ↗
Q3 2016	Sep 30, 2016	2,613	-0.8%	Form 10-Q (filed 2016-11-03) ↗
Q2 2016	Jun 30, 2016	2,813	+2.9%	Form 10-Q (filed 2016-08-03) ↗
Q1 2016	Mar 31, 2016	2,786	+6.2%	Form 10-Q (filed 2016-05-04) ↗
Q4 2015	Dec 31, 2015	2,599	-1.7%	Form 10-K (filed 2016-02-19) ↗
Q3 2015	Sep 30, 2015	2,633	-2.3%	Form 10-Q (filed 2015-11-05) ↗
Q2 2015	Jun 30, 2015	2,735	-3.1%	Form 10-Q (filed 2015-08-04) ↗
Q1 2015	Mar 31, 2015	2,623	-5.5%	Form 10-Q (filed 2015-05-06) ↗
Q4 2014	Dec 31, 2014	2,643	-1.9%	Form 10-K (filed 2015-02-27) ↗
Q3 2014	Sep 30, 2014	2,696	-3.9%	Form 10-Q (filed 2014-11-06) ↗
Q2 2014	Jun 30, 2014	2,823	+3.6%	Form 10-Q (filed 2014-08-05) ↗
Q1 2014	Mar 31, 2014	2,775	+2.4%	Form 10-Q (filed 2014-05-07) ↗
Q4 2013	Dec 31, 2013	2,693	-29.0%	Form 10-K (filed 2014-02-21) ↗
Q3 2013	Sep 30, 2013	2,804	-26.5%	Form 10-Q (filed 2013-11-07) ↗
Q2 2013	Jun 30, 2013	2,725	-22.5%	Form 10-Q (filed 2013-08-06) ↗
Q1 2013	Mar 31, 2013	2,710	-23.6%	Form 10-Q (filed 2013-05-08) ↗
Q4 2012	Dec 31, 2012	3,793	+15.5%	Form 10-K (filed 2014-02-21) ↗
Q3 2012	Sep 30, 2012	3,814	+16.7%	Form 10-Q (filed 2012-11-07) ↗
Q2 2012	Jun 30, 2012	3,518	+1.2%	Form 10-Q (filed 2012-08-07) ↗
Q1 2012	Mar 31, 2012	3,549	+4.4%	Form 10-Q (filed 2012-05-08) ↗
Q4 2011	Dec 31, 2011	3,284	+3.0%	Form 10-K (filed 2012-02-21) ↗
Q3 2011	Sep 30, 2011	3,269	-1.2%	Form 10-Q (filed 2011-11-04) ↗
Q2 2011	Jun 30, 2011	3,475	+9.7%	Form 10-Q (filed 2011-08-04) ↗
Q1 2011	Mar 31, 2011	3,401	-0.3%	Form 10-Q (filed 2011-05-06) ↗
Q4 2010	Dec 31, 2010	3,189	-2.3%	Form 10-K (filed 2011-02-18) ↗
Q3 2010	Sep 30, 2010	3,309	-3.3%	Form 10-Q (filed 2010-11-05) ↗
Q2 2010	Jun 30, 2010	3,169	-10.0%	Form 10-Q (filed 2010-08-05) ↗
Q1 2010	Mar 31, 2010	3,411	–	Form 10-Q (filed 2010-05-04) ↗
Q4 2009	Dec 31, 2009	3,265	+17.6%	Form 10-K (filed 2010-02-19) ↗
Q3 2009	Sep 30, 2009	3,422	–	Form 10-Q (filed 2009-11-06) ↗
Q2 2009	Jun 30, 2009	3,521	–	Form 10-Q (filed 2009-08-07) ↗
Q4 2008	Dec 31, 2008	2,776	-5.9%	Form 10-Q (filed 2009-08-07) ↗
Q4 2007	Dec 31, 2007	2,951	–	Form 10-K (filed 2010-02-19) ↗

Cite this data

StockData. (2026). Abbott Laboratories Total Inventories ($M) ($M), quarterly Q4 2007–Q2 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/db-bs-inv

See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.

Where these numbers come from

Parsed from the XBRL in Abbott Laboratories's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Jun 1, 1998
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABT.

Compare: ABT vs ABBV · ABT vs LLY · ABT vs JNJ · ABT vs PFE · ABT vs VTRS

Revenue growth8.1% · median 8.1%

Gross margin56.6% · median 71.5%

Operating margin15.8% · median 12.8%

Net margin11.6% · median 15.6%

Company	Revenue	Growth
JNJ	$97.93B	+8.1%
LLY	$86.46B	+45.5%
ABBV	$64.39B	+10.4%
PFE	$63.70B	-0.2%
ABT	$46.59B	+8.1%
VTRS	$14.74B	+4.4%

Company

Next earnings (est.): Jan 21, 2027, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 115,000
Held by institutions: 79.8%
Auditor: Ernst & Young LLP
SEC CIK: 1800

Advertisement
300 × 250